Concomitant Adolescent Vaccination in the U.S., 2007–2012 by Moss, Jennifer L. et al.
Concomitant Adolescent Vaccination in the U.S., 2007–2012
Jennifer L. Moss, PhD1,2, Paul L. Reiter, PhD3, and Noel T. Brewer, PhD1,4
1Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina 
2Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, Maryland 3College 
of Medicine, The Ohio State University, Columbus, Ohio 4Lineberger Comprehensive Cancer 
Center, University of North Carolina, Chapel Hill, North Carolina
Abstract
Introduction—Concomitant (same-day) delivery of two or more vaccines to adolescents is 
effective, safe, and efficient. Increasing concomitant vaccination could improve coverage for 
recommended adolescent vaccines, but little is known about who receives vaccines concomitantly.
Methods—Data came from healthcare provider–verified records on 70,144 adolescents (aged 
13–17 years) in the 2008–2012 versions of the National Immunization Survey–Teen who had 
received at least one dose of tetanus, diphtheria, and acellular pertussis (Tdap) booster, 
meningococcal conjugate vaccine (MenACWY), or human papillomavirus (HPV) vaccine. 
Separately for each vaccine, multivariable logistic regression identified adolescent and household 
correlates of concomitant versus single vaccination, stratified by adolescent sex. Vaccination took 
place in 2007–2012, data collection in 2008–2012, and data analysis in 2015.
Results—Among vaccinated adolescents, 51%–65% of girls and 25%–53% of boys received two 
vaccines concomitantly. Concomitant uptake of each vaccine increased over survey years (e.g., 
2012 vs 2008: girls’ Tdap booster, OR=1.88, 95% CI=1.56, 2.26; boys’ Tdap booster, OR=2.62, 
95% CI=2.16, 3.16), with the exception of HPV vaccination among boys. Additionally, 
concomitant vaccination was less common as adolescents got older and in the Northeast (all 
p<0.05). For MenACWY and HPV vaccine, concomitant uptake was less common for girls whose 
mothers had higher versus lower education and for boys who lived in metropolitan versus non-
metropolitan areas (all p<0.05).
Conclusions—Missed opportunities for concomitant adolescent vaccination persist, particularly 
for HPV vaccine. Future interventions targeting groups with low rates of concomitant vaccination 
could improve population-level coverage with recommended vaccines.
Address correspondence to: Jennifer L. Moss, PhD, Cancer Prevention Fellow, Surveillance Research Program, Division of Cancer 
Control and Population Sciences, National Cancer Institute, 9609 Medical Center Drive, Room 4E514, MSC 9765, Bethesda MD 
20892-9765. jennifer.moss@nih.gov; jlmoss@email.unc.edu. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
No other financial disclosures were reported by the authors of this paper.
HHS Public Access
Author manuscript
Am J Prev Med. Author manuscript; available in PMC 2017 November 01.
Published in final edited form as:
Am J Prev Med. 2016 November ; 51(5): 693–705. doi:10.1016/j.amepre.2016.05.013.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Introduction
The Advisory Committee on Immunization Practices recommends that adolescents aged 11–
12 years routinely receive three vaccines: tetanus, diphtheria, and acellular pertussis (Tdap) 
booster, quadrivalent meningococcal conjugate vaccine (MenACWY), and human 
papillomavirus (HPV) vaccine.1 In 2014, national coverage for these vaccines among 
adolescents aged 13–17 years reached 88% for Tdap booster, 79% for MenACWY, and 60% 
and 42% for initiation of the three-dose HPV vaccine series among girls and boys, 
respectively.2 These rates were lower than coverage observed for routine childhood 
vaccinations,3 and coverage levels for MenACWY and HPV vaccine among adolescents 
aged 13–15 years were lower than national goals.4, 5 Failing to improve vaccination 
coverage could result in considerable morbidity and mortality for young people now and as 
they age.1, 6, 7
Concomitant vaccination (also called simultaneous or same-day vaccination) refers to the 
receipt of two or more vaccines during a single healthcare encounter.1, 8 Concomitant 
vaccination maintains each vaccine’s immunogenicity8–13 and safety profile,8–14 and it also 
saves time by reducing the number of healthcare visits needed to complete the adolescent 
vaccination platform. Thus, concomitant vaccination is an efficient way to increase 
adolescent vaccination coverage by reducing missed opportunities,10, 11 especially important 
because adolescents seek preventive health care less often than younger children.15 A 2014 
study from the Centers for Disease Control and Prevention (CDC) estimated that routine 
concomitant vaccination among female adolescents could almost double the rates of HPV 
vaccine initiation and thus substantially reduce risk of HPV-associated diseases.16
Despite these benefits, many parents remain reluctant to consent to concomitant vaccination 
for children and adolescents,17–19 and providers may also hesitate to deliver vaccines 
concomitantly.18–20 Missed opportunities for concomitant vaccination, particularly with 
HPV vaccine, are common.16, 21, 22 Parents’ hesitancies could arise from fears about side 
effects, such as pain or “overburdening” the immune system.23–25 Some clinicians share 
these concerns18, 19 or overestimate parents’ concerns,24 and thus may hesitate to 
recommend concomitant vaccination. Health communication campaigns that target groups 
who are least likely to concomitantly vaccinate could overcome these barriers.
Although some studies have examined the prevalence of having received all three adolescent 
vaccines,26, 27 no studies have investigated the frequency or correlates of concomitant 
adolescent vaccination. The present study examined associations between adolescent and 
household characteristics and concomitant vaccination within a nationally representative 
sample. Findings from this study can inform future programs that intend to increase 
concomitant vaccination and, as a result, increase vaccination coverage.
Methods
Procedures and Sample
Each year, CDC conducts the National Immunization Survey (NIS)-Teen, a population-
based telephone survey of caregivers (hereafter called “parents”) of adolescents aged 13–17 
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years.28 Data for the present study came from the 2008–2012 versions of NIS-Teen. 
Sampling frames for survey years 2008–2010 were U.S. landline phone numbers, and 
sampling frames for survey years 2011–2012 were U.S. landline and cell phone numbers. 
The NIS-Teen interview included questions assessing adolescents’ sociodemographic and 
healthcare information (including adolescent vaccination). If parents provided consent, NIS-
Teen staff verified vaccination through written questionnaires mailed to the clinics of the 
adolescents’ healthcare providers.
For each of 5 survey years, >30,000 parents completed the NIS-Teen phone survey.28 Of 
these, around 65% had provider verification of vaccination history (n=99,921 across survey 
years). Exclusion criteria included non-receipt of any of the three adolescent vaccines 
(n=21,574), as previous studies have already identified correlates of adolescent vaccination 
(single or concomitant) versus non-vaccination, and receipt of vaccines outside of the study 
period (n=8,203).29–32 The study period was January 1, 2007, through December 31, 2012, 
as national guidelines1 began recommending all three routine adolescent vaccines by early 
2007 (for HPV vaccination, the initial recommendation was among girls only33). Although 
data collection for the 2012 NIS-Teen continued into the early months of 2013, vaccinations 
that took place after December 31, 2012 were excluded to allow analysis of time trends 
across whole years. The final analytic sample included 70,144 adolescents. Data analysis 
took place in 2015.
The National Center for Health Statistics Research Ethics Review Board approved data 
collection for NIS-Teen. Analysis of de-identified data from the survey is exempt from 
federal regulations for the protection of human research participants. Analysis of restricted 
data through the National Center for Health Statistics Research Data Center is also approved 
by the National Center for Health Statistics Research Ethics Review Board. The IRB at the 
University of North Carolina exempted this study from review.
Measures
Predictor variables included adolescent and household characteristics gathered during the 
phone interviews across the 5 survey years. Adolescent characteristics were sex (male or 
female), age (range, 13–17 years), race/ethnicity (non-Hispanic white, non-Hispanic black, 
Hispanic, or other), private health insurance status (no or yes), and preventive checkup in the 
last year (no or yes). Household characteristics were mother’s age (≤34 years, 35–44 years, 
or ≥45 years), mother’s education level (high school or less, or at least some college), annual 
household income (below poverty level, above poverty level, or unknown), urbanicity (non-
metropolitan or metropolitan); U.S. Census region of residence (South, Midwest, Northeast, 
or West), and number of children in the household (1 or ≥2). In NIS-Teen reports2 and other 
studies,29–32 these variables have correlated with adolescent vaccination.
Dichotomous indicator variables reflected whether adolescents received Tdap booster, 
MenACWY (one or more dose, though adolescents aged >16 years may receive a booster), 
and HPV vaccine (one or more dose of the three-dose series)1 singly or concomitantly, 
according to provider records. Providers reported the date on which adolescents received 
their vaccines on the written survey. Adolescents were classified as singly vaccinated (coded 
as 0) if they received the target vaccine but no other adolescent vaccine on the same day 
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(e.g., only Tdap booster on a given day). They were classified as concomitantly vaccinated 
(coded as 1) if they received the target vaccine and another adolescent vaccine on the same 
day (e.g., Tdap booster on a given day, with MenACWY or HPV vaccine on the same day). 
Adolescents did not contribute to a model if they did not receive a particular vaccine, but 
they were retained in models of other vaccine(s) they received. MenACWY included 
meningococcal conjugate and unknown type of meningococcal vaccine, following NIS-
Teen.2 To be consistent with other studies,29–32, 34–37 HPV vaccination referred to series 
initiation (receipt of the first dose).
Statistical Analysis
Analyses included multivariable logistic regressions to examine the relationships between 
concomitant vaccination and all of the adolescent and household characteristics described 
above, given their associations with vaccination behaviors in previous studies.29–32 Analyses 
also included NIS-Teen study year. In the regression models, adolescent age was treated as a 
continuous variable.
Because the adolescents in this sample were aged 13–17 years, they were eligible to have 
already received Tdap booster, MenACWY, and HPV vaccine (assuming they had no 
medical contraindications1) when they were aged 11–12 years. The one caveat is for HPV 
vaccine among male adolescents: The Advisory Committee on Immunization Practices 
issued a recommendation for routine HPV vaccination among female adolescents in 2007,33 
but issued a permissive recommendation for HPV vaccination in male adolescents in 2009 
and a recommendation for routine vaccination in 2011.38 Therefore, regression analyses 
were stratified by adolescent sex.
Analyses were implemented in SAS, version 9.2, using a two-tailed p-value of 0.05. NIS-
Teen sampling weights were applied to account for non-equal probability of selection into 
the survey. Results include unweighted frequencies and weighted proportions and effect 
estimates.
Results
Adolescents were fairly evenly distributed across survey year, sex, and age (Table 1). Most 
adolescents were non-Hispanic white (57%), had a preventive checkup in the last year 
(88%), and lived in households above the poverty level (74%). Over the study period (2008–
2012), national vaccination coverage increased for Tdap booster (41% to 85%), MenACWY 
(42% to 74%), and HPV vaccine (37% to 54%, initiation among female adolescents).39 
From 2010 to 2012, HPV vaccine initiation among male adolescents increased from 1% to 
21%.39
Among vaccinated female adolescents, about half received Tdap booster concomitantly with 
another adolescent vaccine, about two thirds received MenACWY concomitantly, and about 
half received HPV vaccine concomitantly (Table 2). For each vaccination outcome, 
concomitant uptake increased over survey years (Table 2, Figure 1A).
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In addition, concomitant Tdap booster vaccination was less common among female 
adolescents who were older (OR=0.81, 95% CI=0.79, 0.84), lived in households with 
unknown income (compared with below poverty level: OR=0.71, 95% CI=0.55, 0.91), and 
lived in the Northeast region (compared with South: OR=0.77, 95% CI=0.68, 0.86) (Table 
2). Concomitant Tdap booster vaccination was also negatively related to mothers’ age, and 
positively related to Hispanic ethnicity and living in metropolitan areas.
Concomitant MenACWY vaccination was less common among female adolescents who 
were older (OR=0.82, 95% CI=0.80, 0.85), whose mothers had higher education (OR=0.80, 
95% CI=0.71, 0.90), who lived in households with higher or unknown incomes (OR=0.81, 
95% CI=0.68, 0.96 and OR=0.75, 95% CI=0.58, 0.96, respectively), and who lived in the 
Northeast region (compared with South: OR=0.66, 95% CI=0.59, 0.74) (Table 2). 
Concomitant MenACWY vaccination was also negatively related to having private health 
insurance, having a preventive checkup in the last year, and mother’s age, and positively 
related to living in the West region.
Concomitant HPV vaccination was less common among female adolescents who were older 
(OR=0.87, 95% CI=0.83, 0.90), whose mothers had higher education (OR=0.85, 95% 
CI=0.75, 0.96), and who lived in the Northeast region (compared with South: OR=0.74, 95% 
CI=0.65, 0.84) (Table 2). Concomitant HPV vaccination was also negatively related to 
having private health insurance, and positively related to living in the West region.
Among vaccinated male adolescents, about half received Tdap booster concomitantly with 
another adolescent vaccine, about half received MenACWY concomitantly, and only one 
quarter received HPV vaccine concomitantly (Table 3). For Tdap booster and MenACWY, 
concomitant uptake increased over survey years (Table 3, Figure 1B).
In addition, concomitant Tdap booster vaccination was less common among male 
adolescents who were older (OR=0.74, 95% CI=0.72, 0.77) and who lived in the Northeast 
region (compared with South: OR=0.78, 95% CI=0.70, 0.87). Concomitant Tdap booster 
vaccination was also positively related to non-Hispanic black race/ethnicity, Hispanic 
ethnicity, and living in metropolitan areas.
Concomitant MenACWY vaccination was less common among male adolescents who were 
older (OR=0.65, 95% CI=0.62, 0.67), who lived in metropolitan areas (OR=0.85, 95% 
CI=0.75, 0.96), and who lived in the Northeast region (compared with South: OR=0.68, 95% 
CI=0.61, 0.77). Concomitant MenACWY vaccination was also positively related to non-
Hispanic black race/ethnicity and living in the Midwest or West regions, and negatively 
related to having a preventive checkup in the last year.
Concomitant HPV vaccination was less common among male adolescents who were older 
(OR=0.71, 95% CI=0.62, 0.81), who lived in metropolitan areas (OR=0.49, 95% CI=0.33, 
0.73), and who lived in the Northeast region (compared with South: OR=0.43, 95% CI=0.25, 
0.76).
Moss et al. Page 5
Am J Prev Med. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Discussion
Missed opportunities for concomitant vaccination were common, with two thirds or less of 
U.S. adolescents who had initiated vaccination receiving two doses during the same 
healthcare visit. However, the frequency of concomitant administration has increased for 
most vaccines since 2008. Clear differences in concomitant vaccination emerged among key 
demographic groups. Future public health promotion campaigns could encourage this 
behavior among targeted subgroups in order to safely, effectively, and efficiently increase 
adolescent vaccination coverage and protect against future disease.
Important temporal patterns to concomitant vaccination emerged, specifically around survey 
year and adolescent age. Almost all of the concomitant vaccination outcomes demonstrated 
clear increases over the survey years. It is possible that, in the years since the introduction of 
the national guidelines for routine vaccination, adolescents and their parents have become 
more accustomed to the doses in the adolescent vaccination platform, increasing their 
acceptability individually and in combination, or that providers have become more 
comfortable recommending concomitant vaccination. Concomitant HPV vaccination among 
boys may not have demonstrated the same pattern owing to the low rates of this behavior in 
general, which precluded the detection of stable trends. In addition, concomitant vaccination 
was less common among adolescents who were older at the time of their parents’ 
participation in NIS-Teen. Again, this pattern could have emerged because of the relatively 
higher acceptability of vaccines in more recent years (when younger adolescents would have 
become eligible to receive their vaccines). Alternatively, providers may be more comfortable 
delivering multiple vaccines concomitantly when adolescents are aged 11–12 years, given 
that most of the safety and efficacy data have focused on younger adolescents. Future studies 
should monitor trends in concomitant (versus single) vaccination over time and how these 
contribute to trends in overall vaccination coverage.
Another consistent pattern was that, compared with adolescents living in the South, 
adolescents in the Northeast were less likely to receive every vaccine concomitantly. 
However, adolescents in the West were more likely to concomitantly receive MenACWY 
(girls and boys) or HPV vaccine (girls only). These findings provide a contrast to the NIS-
Teen reports of overall vaccination coverage,2 which indicate that, generally, states in the 
Northeast and West regions have the highest rates of coverage in the nation. Thus, high rates 
of vaccination coverage have emerged in the Northeast, despite the low rates of concomitant 
vaccination, and high rates of vaccination coverage have emerged in the West, potentially 
due (at least in part) to the high rates of concomitant vaccination. One potential explanation 
for this pattern is the high density of healthcare providers (both in terms of pediatricians40 
and in school-located health centers41) in the Northeast; adolescents in that region who did 
not receive their vaccines concomitantly had relatively easy access to healthcare facilities 
where they could return for multiple visits to receive vaccines individually. A recent study 
by Jeyarajah and colleagues22 found a similar pattern, reporting that HPV vaccination by age 
13 years among adolescent females was highest in the West, despite the overall higher levels 
of coverage in the Northeast; clearly, vaccination patterns, including concomitant and on-
time uptake, vary meaningfully across the U.S.
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Among adolescent girls, concomitant vaccination differed by SES and healthcare access. 
Girls living in households below the federal poverty level and whose mothers had the lowest 
education were more likely to concomitantly vaccinate, especially with MenACWY. Vaccine 
refusal or delay42, 43 is less common lower-SES families than higher-SES families, and these 
patterns likely extend to concomitant vaccination. A related pattern was that girls who did 
not have private health insurance and did not have a recent preventive checkup were more 
likely to concomitantly vaccinate, especially with MenACWY. These families, who may not 
have easy or consistent access to healthcare providers,44 may be especially motivated to 
concomitantly vaccinate because returning to the medical office to receive individual 
vaccines could be prohibitive. More research is needed to understand parents’ motivations 
for concomitant vaccination.
Finally, there were no consistent patterns in concomitant vaccination by race/ethnicity. 
Though descriptively, non-Hispanic white adolescents had the lowest rates for most of the 
concomitant vaccination outcomes, these differences were not generally statistically 
significant in the multivariable models. These results reflect a pattern toward increased 
concomitant vaccination among minority adolescents, which stands in contrast to findings 
that minorities have less favorable attitudes toward vaccines.45 However, it is possible that 
these racial/ethnic patterns in concomitant vaccination are confounded with measures of 
healthcare access (described above). Given that minorities are less likely to have access to 
high-quality preventive health care,46 they may be more accepting of concomitant 
vaccination because of the challenge they may face in returning to the medical office for 
individual administration of vaccines. Future studies should monitor racial/ethnic differences 
in concomitant vaccination, especially as the Affordable Care Act makes preventive 
healthcare services more accessible.47
In terms of study strengths, data came from a large, nationally representative, multiyear 
sample.28 In addition, NIS-Teen includes provider verification of vaccination, which was 
crucial to the operationalization of concomitant vaccination (i.e., determining if adolescents 
received more than one vaccination on the same day, according to medical records). 
Moreover, this study is the first investigation of correlates of concomitant vaccination, a 
behavior noted as crucial to increasing vaccination coverage by CDC, the American 
Academy of Pediatrics, the American Academy of Family Physicians, and the American 
Medical Association.1, 16, 48
Limitations
In terms of study limitations, the 2008–2010 NIS-Teen exclusively used landline phone 
numbers to contact participants, whereas in 2011–2012, they also contacted participants 
through cell phone numbers; this difference in data collection mode could introduce some 
systematic differences in samples across years. Each year’s NIS-Teen sample is intended to 
be representative of a given calendar year28 and combining across years creates an average 
and not a valid representation of vaccination behaviors at a given time. In addition, this 
preliminary investigation of the frequency and correlates of concomitant vaccination focused 
on demographic characteristics of adolescents and their households; other factors, including 
those related to adolescents’ contraindications for vaccination, local attitudes and norms, 
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healthcare policies, and provider behaviors,20 may also contribute to concomitant 
vaccination. Additional studies are needed to parse the relationships among these variables 
and concomitant vaccination, especially in subgroups with low rates of concomitant 
vaccination. Similarly, this investigation was limited to only Tdap booster, MenACWY (first 
dose), and HPV vaccine (first dose), excluding concomitant administration of other vaccines 
(e.g., seasonal influenza vaccine, catchup of childhood vaccines); thus, the prevalence of 
concomitant vaccination among adolescents may be underestimated. Finally, the Advisory 
Committee on Immunization Practices released their recommendation for routine HPV 
vaccination in girls in March 2007, which could have reduced concomitant HPV vaccination 
during 2007, potentially leading to artificially inflated estimates of time trends in 
concomitant vaccination in later survey years. However, given the consistency of the 
increases in concomitant vaccination each year (except for HPV vaccination among boys), 
this pattern does not appear to have unduly influenced the findings.
Conclusions
Missed opportunities for concomitant adolescent vaccination are common, though 
concomitant vaccination seems to be increasing over time. Subgroups with lower rates of 
concomitant vaccination include adolescents who are older, live in the Northeast, and have 
higher SES and better healthcare access. Future public health interventions could build upon 
these findings to target subgroups that are less prone to concomitant adolescent vaccination 
in order to promote this behavior. Increases in concomitant vaccination and vaccination 
coverage will confer more protection for adolescents from several infectious and chronic 
diseases, including multiple types of cancer, both now and as they get older.
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Figure 1. 
Concomitant uptake of adolescent vaccines for (A) female and (B) male adolescents across 
years of participation in National Immunization Survey (NIS)-Teen.
Notes: Tdap, tetanus, diphtheria, and acellular pertussis booster; MenACWY, meningococcal 
conjugate and unknown types of meningococcal vaccine; HPV, human papillomavirus 
vaccine (first dose)
Errors bars represent SEs.
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 sm
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tio
ns
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